Amgen Inc. (NASDAQ: AMGN) Stock Competitors & Peer Comparison
See AMGN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMGN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMGN | $410.95 | +1.51% | 221.8B | 18.37 | $22.37 | +2.39% |
| LLY | $1,185.71 | -0.52% | 1.1T | 37.64 | $31.49 | +0.55% |
| JNJ | $259.24 | +0.88% | 624.7B | 24.16 | $10.73 | +2.04% |
| ABBV | $246.04 | +0.89% | 434.4B | 24.13 | $10.19 | +2.79% |
| MRK | $128.57 | +0.16% | 317.5B | 40.05 | $3.21 | +2.61% |
| NVS | $156.33 | +1.37% | 297.2B | 17.99 | $8.69 | +3.03% |
| AZN | $161.42 | +0.88% | 250.3B | 17.43 | $9.26 | +1.30% |
| NVO | $47.26 | +2.81% | 209.8B | 11.75 | $4.02 | +3.82% |
| GILD | $133.21 | +1.80% | 165.4B | -341.56 | -$0.39 | +2.42% |
| PFE | $26.76 | +2.14% | 152.4B | 8.77 | $3.05 | +6.47% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
AMGN vs LLY Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while LLY trades at $1,185.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas LLY's P/E ratio is 37.64. In terms of profitability, AMGN's ROE is +0.89%, compared to LLY's ROE of +0.93%. Regarding short-term risk, AMGN is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
AMGN vs JNJ Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, JNJ has a market cap of 624.7B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while JNJ trades at $259.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas JNJ's P/E ratio is 24.16. In terms of profitability, AMGN's ROE is +0.89%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, AMGN is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
AMGN vs ABBV Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, ABBV has a market cap of 434.4B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while ABBV trades at $246.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas ABBV's P/E ratio is 24.13. In terms of profitability, AMGN's ROE is +0.89%, compared to ABBV's ROE of -1.37%. Regarding short-term risk, AMGN is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
AMGN vs MRK Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, MRK has a market cap of 317.5B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while MRK trades at $128.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas MRK's P/E ratio is 40.05. In terms of profitability, AMGN's ROE is +0.89%, compared to MRK's ROE of +0.18%. Regarding short-term risk, AMGN is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check MRK's competition here
Novartis AG (NYSE: NVS)
AMGN vs NVS Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, NVS has a market cap of 297.2B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while NVS trades at $156.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas NVS's P/E ratio is 17.99. In terms of profitability, AMGN's ROE is +0.89%, compared to NVS's ROE of +0.30%. Regarding short-term risk, AMGN is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
AMGN vs AZN Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, AZN has a market cap of 250.3B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while AZN trades at $161.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas AZN's P/E ratio is 17.43. In terms of profitability, AMGN's ROE is +0.89%, compared to AZN's ROE of +0.22%. Regarding short-term risk, AMGN is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check AZN's competition here
Novo Nordisk A/S (NYSE: NVO)
AMGN vs NVO Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, NVO has a market cap of 209.8B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while NVO trades at $47.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas NVO's P/E ratio is 11.75. In terms of profitability, AMGN's ROE is +0.89%, compared to NVO's ROE of +0.59%. Regarding short-term risk, AMGN is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
AMGN vs GILD Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, GILD has a market cap of 165.4B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while GILD trades at $133.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas GILD's P/E ratio is -341.56. In terms of profitability, AMGN's ROE is +0.89%, compared to GILD's ROE of -0.16%. Regarding short-term risk, AMGN is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
AMGN vs PFE Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, PFE has a market cap of 152.4B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while PFE trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas PFE's P/E ratio is 8.77. In terms of profitability, AMGN's ROE is +0.89%, compared to PFE's ROE of +0.05%. Regarding short-term risk, AMGN is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
AMGN vs BMY Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, BMY has a market cap of 132.2B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while BMY trades at $64.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas BMY's P/E ratio is 10.91. In terms of profitability, AMGN's ROE is +0.89%, compared to BMY's ROE of +0.47%. Regarding short-term risk, AMGN is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check BMY's competition here
GSK plc (NYSE: GSK)
AMGN vs GSK Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, GSK has a market cap of 106.1B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while GSK trades at $52.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas GSK's P/E ratio is 11.44. In terms of profitability, AMGN's ROE is +0.89%, compared to GSK's ROE of +0.24%. Regarding short-term risk, AMGN is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check GSK's competition here
Sanofi (NASDAQ: SNY)
AMGN vs SNY Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, SNY has a market cap of 104.4B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while SNY trades at $43.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas SNY's P/E ratio is 9.47. In terms of profitability, AMGN's ROE is +0.89%, compared to SNY's ROE of +0.06%. Regarding short-term risk, AMGN is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check SNY's competition here
Biogen Inc. (NASDAQ: BIIB)
AMGN vs BIIB Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, BIIB has a market cap of 30.7B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while BIIB trades at $207.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas BIIB's P/E ratio is 13.13. In terms of profitability, AMGN's ROE is +0.89%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, AMGN is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check BIIB's competition here
Zoetis Inc. (NYSE: ZTS)
AMGN vs ZTS Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, ZTS has a market cap of 30.5B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while ZTS trades at $72.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas ZTS's P/E ratio is 11.04. In terms of profitability, AMGN's ROE is +0.89%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, AMGN is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check ZTS's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
AMGN vs HZNP Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AMGN's ROE is +0.89%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AMGN is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
AMGN vs GRFS Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, GRFS has a market cap of 6.7B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while GRFS trades at $7.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas GRFS's P/E ratio is 9.12. In terms of profitability, AMGN's ROE is +0.89%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, AMGN is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
AMGN vs OGN Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while OGN trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas OGN's P/E ratio is 4.06. In terms of profitability, AMGN's ROE is +0.89%, compared to OGN's ROE of +0.23%. Regarding short-term risk, AMGN is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
AMGN vs CELG-RI Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, CELG-RI has a market cap of 224.5M. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while CELG-RI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.89%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, AMGN is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
AMGN vs CTOR Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, CTOR has a market cap of 72.5M. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while CTOR trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas CTOR's P/E ratio is -1.66. In terms of profitability, AMGN's ROE is +0.89%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, AMGN is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLX)
AMGN vs SCLX Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, SCLX has a market cap of 59M. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while SCLX trades at $6.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas SCLX's P/E ratio is -0.18. In terms of profitability, AMGN's ROE is +0.89%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, AMGN is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
AMGN vs SCLXW Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, SCLXW has a market cap of 58.9M. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while SCLXW trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas SCLXW's P/E ratio is -0.01. In terms of profitability, AMGN's ROE is +0.89%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, AMGN is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
AMGN vs MIRA Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, MIRA has a market cap of 31.1M. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while MIRA trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas MIRA's P/E ratio is -0.51. In terms of profitability, AMGN's ROE is +0.89%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, AMGN is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
AMGN vs BDSIW Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, AMGN's ROE is +0.89%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, AMGN is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
AMGN vs CRXT Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 221.8B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AMGN is priced at $410.95 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 18.37, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AMGN's ROE is +0.89%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AMGN is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check CRXT's competition here